steven c gilman phd  contrafect corporation cfrx nasdaq cfrx steven c gilman phd about us home about us management team about us steven c gilman phd chairman and chief executive officer dr gilman most recently served as the executive vice president research  development and chief scientific officer at cubist pharmaceuticals until its acquisition by merck  co prior to joining cubist in  dr gilman served as chairman of the board of directors and chief executive officer of activbiotics a privately held biopharmaceutical company previously dr gilman worked at millennium pharmaceuticals inc where he held a number of senior leadership roles including vice president and general manager of the inflammation franchise responsible for all aspects of the inflammation business from early gene discovery to product commercialization prior to millennium he was group director at pfizer global research and development where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas dr gilman has also held scientific business and academic appointments at wyeth cytogen corporation temple medical school and connecticut college dr gilman currently serves on the board of directors of publicly traded companies keryx biopharmaceuticals inc momenta pharmaceuticals inc scynexis inc and vericel corporation dr gilman received his phd and ms degrees in microbiology from pennsylvania state university his postdoctoral training at scripps clinic and research foundation and received a ba in microbiology from miami university of ohio he has authored over  publications and is an inventor on  patents steven gilman  cubist pharmaceuticals  inc  zoominfocom gilman steven c  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address  concord belmont ma   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwinssretswins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  cfrxcontrafect corpdehealthdrugpharmaceutical preparationsgilman steven cmadoceopdd  cfrxcontrafect corpdehealthdrugpharmaceutical preparationsgilman steven cnydoceopdnewd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdmd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdmd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemadd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesadd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdmd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdmd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiesdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaoevpchiemdmd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaosvpchiemdd  cbstcubist pharmaceuticals incdehealthdrugpharmaceutical preparationsgilman steven cmaosvpchiesdd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved momenta pharmaceuticals appoints steven c gilman phd to board of directors nasdaqmnta jun   previous release  next release pdf add to briefcase file is in briefcase momenta pharmaceuticals appoints steven c gilman phd to board of directors cambridge mass june   globe newswire  momenta pharmaceuticals inc nasdaqmnta a biotechnology company specializing in the characterization and engineering of complex drugs today announced the appointment of steven c gilman phd to its board of directors effective june    dr gilman was most recently executive vice president research  development and chief scientific officer at cubist pharmaceuticals until its acquisition by merck  co in january  steve brings a strong set of biopharmaceutical research and development expertise and i am very pleased that he has decided to join our board said craig wheeler president and ceo momenta pharmaceuticals his wealth of experience in building and leading novel immunology and inflammation drug development programs will be of significant importance as we work to rapidly advance our biosimilar and novel autoimmune drug portfolios toward commercialization   momenta also announced today that bennett m shapiro md will no longer serve as a member of momentas board of directors following completion of his term ending on june    dr shapiro was a member of the board of directors since  serving on the science compensation and nominating and corporate governance committees id like to thank ben for his many years of invaluable support in building momenta into the company it is today with two complex generic products on the market and a robust portfolio of biosimilar and novel drug candidates we wish him well in his future endeavors continued mr wheeler dr gilman currently serves as the executive chairman and interim ceo of contrafect corporation nasdaqcfrx and as a member of the board of directors of vericel nasdaqvcel scynexis nasdaqscyx and keryx nasdaqkerx he also serves as a member of the board of directors of the northeastern university drug discovery advisory board the massachusetts biotechnology association and the penn state university biotechnology advisory board prior to joining cubist dr gilman served as chairman of the board of directors and ceo of activbiotics a privately held biopharmaceutical company previously dr gilman worked at millennium pharmaceuticals inc where he held a number of senior leadership roles including vice president and general manager of the inflammation franchise prior to millennium he was group director at pfizer central research where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas dr gilman has also held scientific business and academic appointments at wyeth cytogen corporation temple university school of medicine and connecticut college dr gilman received his phd and ms degrees in microbiology from pennsylvania state university his postdoctoral training at scripps clinic and research foundation and received a ba in microbiology from miami university of ohio about momenta momenta pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in cambridge ma momenta is applying its technology to the development of generic versions of complex drugs biosimilar and potentially interchangeable biologics and to the discovery and development of novel therapeutics for oncology and autoimmune indications to receive additional information about momenta please visit the website at wwwmomentapharmacom which does not form a part of this press release our logo trademarks and service marks are the property of momenta pharmaceuticals inc all other trade names trademarks or service marks are property of their respective owners forward looking statements statements in this press release regarding managements future expectations beliefs intentions goals strategies plans or prospects are forwardlooking statements within the meaning of the private securities litigation reform act of  including but not limited to statements about dr gilman benefitting the company advancing our product pipeline and bringing multiple products to market in the coming years  forwardlooking statements may be identified by words such as will work and other similar words or expressions or the negative of these words or similar words or expressions such forwardlooking statements involve known and unknown risks uncertainties and other factors including those referred to under the section risk factors in the companys quarterly report on form q for the month ended march   filed with the securities and exchange commission as well as other documents that may be filed by the company from time to time with the securities and exchange commission as a result of such risks uncertainties and factors the companys actual results may differ materially from any future results performance or achievements discussed in or implied by the forwardlooking statements contained herein the company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forwardlooking statements whether as a result of new information future events or otherwise investor contact sarah carmody momenta pharmaceuticals  irmomentapharmacom media contact karen sharma macdougall biomedical communications  momentamacbiocomcom source momenta pharmaceuticals inc news provided by acquire media steven c gilman phd executive profile  biography  bloomberg july    pm et biotechnology company overview of contrafect corporation snapshotpeople  overviewboard memberscommittees executive profile steven c gilman phdexecutive chairman chief executive officer and president contrafect corporationagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr steven c gilman also known as steve phd has been the chief executive officer and president of contrafect corporation since july   and as its executive chairman since may   dr gilman is on leave of absence dr gilman served as an interim chief executive officer of contrafect corporation from march   to july   dr gilman served as the chief scientific officer at cubist pharmaceuticals inc since february  and served as its  executive vice president of research  development since september  he has more than  years of drug research and development experience he served as a senior vice president of discovery  non clinical development at cubist pharmaceuticals inc from february  to september  he served as the chairman of the board of activbiotics inc from may   to february  and also as its chief executive officer from march  to february  and president from march  to may   he served as the chief executive officer and president of activbiotics canada inc a subsidiary of activbiotics inc while at activbiotics he led the transition of the activbiotics from early researchacademic stage to focus on advanced product development and commercialization he served as vice president and general manager of inflammation franchise of millennium pharmaceuticals inc where he held a number of senior leadership roles including vice president and general manager of the inflammation franchise he served as group director of pfizer global research and development where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas he has also held scientific business and academic appointments at wyeth cytogen corporation temple medical school and connecticut college he was responsible for pharmaceutical research units at sterling winthrop and wyeth laboratories in areas including chronic inflammatory diseases transplant rejection autoimmune diseases and bacterial infections he has been a director of momenta pharmaceuticals inc since june   he has been an independent director of keryx biopharmaceuticals inc since april   scynexis inc since february   and vericel corporation since january  he has been a director of contrafect corporation since may   he serves on the biotechnology advisory board of penn state university he serves on director of the massachusetts biotechnology council and nextcea inc he serves as a director of the northeastern university drug discovery advisory board he served as a director of inhibikase therapeutics inc from may  to january   he served as a director of activbiotics inc since march  dr gilman received his ba degree from miami university ohio and his ms and phd degrees in microbiology from pennsylvania state university he completed a postdoctoral research fellowship in the department of immunopathology at the scripps clinic and research foundationread full background corporate headquarters  wells avenueyonkers new york united statesphone fax  board members memberships presentindependent directorvericel corporationpresentindependent directorscynexis incpresentexecutive chairman chief executive officer and presidentcontrafect corporationpresentindependent directorkeryx biopharmaceuticals incpresentdirectormomenta pharmaceuticals inc education ms pennsylvania state universityphd pennsylvania state universityba miami university other affiliations vericel corporationcubist pharmaceuticals llckeryx biopharmaceuticals incscynexis incactivbiotics incpennsylvania state universitymiami universitymomenta pharmaceuticals incactivbiotics canada incinhibikase therapeutics inc annual compensation salarybonustotal annual compensation stocks options all other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact contrafect corporation please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close momenta pharmaceuticals appoints steven c gilman phd to board of directors  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street momenta pharmaceuticals appoints steven c gilman phd to board of directors globenewswire jun    am edt prior to joining cubist dr gilman served as chairman of the board of directors and ceo of activbiotics a privately held biopharmaceutical company previously dr gilman worked at millennium pharmaceuticals inc where he held a number of senior leadership roles including vice president and general manager of the inflammation franchise prior to millennium he was group director at pfizer central research where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas dr gilman has also held scientific business and academic appointments at wyeth cytogen corporation temple university school of medicine and connecticut college dr gilman received his phd and ms degrees in microbiology from pennsylvania state university his postdoctoral training at scripps clinic and research foundation and received a ba in microbiology from miami university of ohio about momenta momenta pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in cambridge ma momenta is applying its technology to the development of generic versions of complex drugs biosimilar and potentially interchangeable biologics and to the discovery and development of novel therapeutics for oncology and autoimmune indications to receive additional information about momenta please visit the website at  wwwmomentapharmacom which does not form a part of this press release our logo trademarks and service marks are the property of momenta pharmaceuticals inc all other trade names trademarks or service marks are property of their respective owners forward looking statements statements in this press release regarding managements future expectations beliefs intentions goals strategies plans or prospects are forwardlooking statements within the meaning of the private securities litigation reform act of  including but not limited to statements about dr gilman benefitting the company advancing our product pipeline and bringing multiple products to market in the coming years  forwardlooking statements may be identified by words such as will work and other similar words or expressions or the negative of these words or similar words or expressions such forwardlooking statements involve known and unknown risks uncertainties and other factors including those referred to under the section risk factors in the companys quarterly report on form q for the month ended march   filed with the securities and exchange commission as well as other documents that may be filed by the company from time to time with the securities and exchange commission as a result of such risks uncertainties and factors the companys actual results may differ materially from any future results performance or achievements discussed in or implied by the forwardlooking statements contained herein the company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forwardlooking statements whether as a result of new information future events or otherwise if you liked this article you might like drug price inflation and a patent cliff could trigger a wave of deals in generic drugs space generic drugmakers are likely to limit themselves to acquisitions of small and midsized companies in the immediate future because of overleveraging and turmoil in the executive ranks william mcconnell jun    pm edt analysts actions  discovery first solar momenta vf corp and more here are wednesdays top research calls including downgrades for discovery first solar and momenta and an upgrade for vf corp thestreet staff feb    am est sarepta leads biotech movers on voucher deal news gilead finally has acquired something from sarepta even if it is quite small alicia mcelhaney feb    am est mylans shares rise despite ftc investigation the drug company saw its stock climb  tuesday on news that it can move ahead with generic copaxone alicia mcelhaney jan    am est trending how amazon billionaire jeff bezos gained vast riches and a tech giant someday worth  trillion jim cramer nails starbucks big decline warns again of downside to  heres why snaps stock could be in for another big plunge on monday teslas model  arrives on friday  heres everything you need to know about this overhyped ride ipod nano shuffle are dead here are  other discontinued apple products advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft contrafect chairman steven c gilman returns from temporary medical leavehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballcontrafect chairman steven c gilman returns from temporary medical leavemarketwiredmay  reblogsharetweetshareyonkers nymarketwired  may    contrafect corporation cfrx a clinicalstage biotechnology company focused on the discovery and development of protein and antibody therapeutics for lifethreatening drugresistant infectious diseases today announced that steven c gilman phd the chairman of contrafects board of directors intends to return from his temporary medical leave to resume his role as chief executive officer on june  i want to thank the companys senior management team for maintaining focus and momentum during my temporary leave i look forward to resuming my duties as ceo and helping to advance contrafects mission to provide important new therapies for patients with lifethreatening infectious diseases said dr gilmanabout contrafectcontrafect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for lifethreatening drugresistant infectious diseases particularly those treated in hospital settings an estimated  deaths worldwide each year are attributed to drugresistant bacterial infections we intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses regions that are not prone to mutation in addition to cf the companys preclinical programs include potential novel lysins for the treatment of drug resistant gramnegative pathogens as well as a monoclonal antibody program targeted for the treatment of viral influenzaforwardlooking statementsthis press release contains forwardlooking statements within the meaning of the us federal securities laws forwardlooking statements can be identified by words such as can may will could would should believes expects anticipates estimates intends plans potential or similar references to future periods and include statements in this release regarding our ability to address life threatening infections using our therapeutic product candidates from our lysin and antibody platforms by targeting conserved regions of either bacteria or viruses our ability to discover and develop protein and antibody therapeutics for lifethreatening drugresistant infectious diseases dr gilmans intent to return from his medical leave on june   and advancing contrafects mission forwardlooking statements are statements that are not historical facts nor assurances of future performance instead they are based on contrafects current beliefs expectations and assumptions regarding the future of its business future plans strategies projections anticipated events and trends the economy and other future conditions because forwardlooking statements relate to the future they are subject to inherent risks uncertainties and changes in circumstances that are difficult to predict and many of which are beyond contrafects control including the effects progress and outcomes of dr gilmans medical treatments and the other important factors detailed in contrafects filings with the securities and exchange commission actual results may differ from those set forth in the forwardlooking statements any forwardlooking statement made by contrafect in this press release is based only on information currently available and speaks only as of the date on which it is made except as required by applicable law contrafect expressly disclaims any obligations to publicly update any forwardlooking statements whether written or oral that may be made from time to time whether as a result of new information future developments or otherwisereblogsharetweetsharerecently viewedyour list is emptywhat to read nextfinish your antibiotics course maybe not experts sayafpthis will be in everyones household by banyan hillsponsoredchild born with hiv is virtually virusfree for  years without medslivesciencecomtrump names john kelly new chief of staff reince priebus outcnbcthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsorednorth korea nd icbm test puts much of us in range expertsassociated presschevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekprotect your new galaxy ssamsungsponsoredthe real reason overseas manufacturing is coming to americayahoo financehere are the us targets north korea most likely wants to nukebusiness insidertax cuts just got more likelyyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsoredmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videoblue apron bullish calls not all theyre cooked up to beyahoo financedonald trump tweetrages after john mccain kills obamacare skinny repealstan let trump rage mccain you did the right thingjoin the conversation  k momenta pharmaceuticals appoints steven c gilman phd to board of directors – pm nasdaqmomenta pharmaceuticals appoints steven c linkedin cancer genetics inc and sayre type in your search and press enter nasdaq momenta pharmaceuticals appoints steven c gilman phd to board of directorsnasdaqnasdaq oncology market newsmomenta pharmaceuticals appoints steven c gilman phd to board of directors bynasdaq market newsjune   facebook twitter linkedin linkedinshares cambridge mass june   globe newswire  momenta pharmaceuticals inc nasdaqmnta a biotechnology company specializing in the characterization and engineering of complex drugs today announced the appointment of steven c gilman phd to its board of directors effective june    dr gilman was most recently executive vice president research  development and chief scientific officer at cubist pharmaceuticals until its acquisition by merck  co in january  steve brings a strong set of biopharmaceutical research and development expertise and i am very pleased that he has decided to join our board said craig wheeler president and ceo momenta pharmaceuticals “his wealth of experience in building and leading novel immunology and inflammation drug development programs will be of significant importance as we work to rapidly advance our biosimilar and novel autoimmune drug portfolios toward commercialization”   momenta also announced today that bennett m shapiro md will no longer serve as a member of momenta’s board of directors following completion of his term ending on june    dr shapiro was a member of the board of directors since  serving on the science compensation and nominating and corporate governance committees id like to thank ben for his many years of invaluable support in building momenta into the company it is today with two complex generic products on the market and a robust portfolio of biosimilar and novel drug candidates we wish him well in his future endeavors continued mr wheeler dr gilman currently serves as the executive chairman and interim ceo of contrafect corporation nasdaqcfrx and as a member of the board of directors of vericel nasdaqvcel scynexis nasdaqscyx and keryx nasdaqkerx he also serves as a member of the board of directors of the northeastern university drug discovery advisory board the massachusetts biotechnology association and the penn state university biotechnology advisory board prior to joining cubist dr gilman served as chairman of the board of directors and ceo of activbiotics a privately held biopharmaceutical company previously dr gilman worked at millennium pharmaceuticals inc where he held a number of senior leadership roles including vice president and general manager of the inflammation franchise prior to millennium he was group director at pfizer central research where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas dr gilman has also held scientific business and academic appointments at wyeth cytogen corporation temple university school of medicine and connecticut college dr gilman received his phd and ms degrees in microbiology from pennsylvania state university his postdoctoral training at scripps clinic and research foundation and received a ba in microbiology from miami university of ohio about momenta momenta pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in cambridge ma momenta is applying its technology to the development of generic versions of complex drugs biosimilar and potentially interchangeable biologics and to the discovery and development of novel therapeutics for oncology and autoimmune indications to receive additional information about momenta please visit the website at wwwmomentapharmacom which does not form a part of this press release our logo trademarks and service marks are the property of momenta pharmaceuticals inc all other trade names trademarks or service marks are property of their respective owners forward looking statements statements in this press release regarding managements future expectations beliefs intentions goals strategies plans or prospects are forwardlooking statements within the meaning of the private securities litigation reform act of  including but not limited to statements about dr gilman benefitting the company advancing our product pipeline and bringing multiple products to market in the coming years  forwardlooking statements may be identified by words such as will work and other similar words or expressions or the negative of these words or similar words or expressions such forwardlooking statements involve known and unknown risks uncertainties and other factors including those referred to under the section risk factors in the companys quarterly report on form q for the month ended march   filed with the securities and exchange commission as well as other documents that may be filed by the company from time to time with the securities and exchange commission as a result of such risks uncertainties and factors the companys actual results may differ materially from any future results performance or achievements discussed in or implied by the forwardlooking statements contained herein the company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forwardlooking statements whether as a result of new information future events or otherwise contact investor contact sarah carmody momenta pharmaceuticals  irmomentapharmacom media contact karen sharma macdougall biomedical communications  momentamacbiocomcom facebook twitter linkedin linkedinshares nasdaq market newsclick here to email authornext storycancer genetics inc and sayre therapeutics announce distribution agreement to commercialize cgi’s proprietary fdacleared tissue of origin too® test throughout india and south asiaprev storyinvestigational wnt inhibitor shows promise in knee osteoarthritissubscribe to pmfollow usexperts on callbrenda snowauthentic patient voiceamy groggrare disease  orphan drug commercialization john weinman phdhealth psychologyrichard meyerdtc marketingchris dowdpatient loyaltydon feilerbrand engagementrick ratliffemrehr connectionsjeffrey d erblife sciences medical strategy erik daltonhcp engagementjessica brueggemanpatientprovider dialoguebud bilanichsuccess coach get in touch with pm experts on calladsyou may also likenasdaqnasdaq mental health market newsdoctors administrative solutions acquires conxit technology group forms national health it  management solutions firm das healthtampa fla jan   globe newswire  united by a common business culture nasdaq market newsjanuary  nasdaqnasdaq mental health market newslightlake therapeutics inc announces collaboration with nida and the perelman school of medicine at the university of pennsylvanianew york dec   globe newswire  lightlake therapeutics inc “lightlake” otcqblltp a nasdaq market newsjanuary  nasdaqnasdaq mental health market newscaresource foundation awards  million to ohio nonprofit organizations in dayton ohio dec   globe newswire  the caresource foundation has announced the nasdaq market newsjanuary   contrafect corporation names steven c gilman phd chief executive officerhomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballcontrafect corporation names steven c gilman phd chief executive officermarketwiredjuly  reblogsharetweetshareyonkers nymarketwired  july    contrafect corporation cfrx cfrxw contrafect we or the company a biotechnology company focused on the discovery and development of protein and antibody therapeutics for lifethreatening drugresistant infectious diseases today announced that it has named steven c gilman phd as chief executive officer of contrafect effective immediately dr gilman has served as interim chief executive officer since march   he will continue to serve as chairman of the board of directors of the companythe board is pleased to have an executive with the experience and credentials of steve gilman to serve as chief executive officer at contrafect said sol barer contrafects lead independent director steve is a proven leader in the infectious disease field and has extensive experience in the development and commercialization of new antiinfective agentsin my time as interim chief executive officer i have worked closely with our team and am excited at the opportunity to bring forward the programs at contrafect and support the companys mission of creating new treatments for lifethreatening infectious diseases said dr gilmanabout contrafect contrafect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for lifethreatening drugresistant infectious diseases particularly those treated in hospital settings an estimated  deaths worldwide each year are attributed to antimicrobialresistant infections we intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses regions that are not prone to mutation contrafects initial product candidates include new agents to treat antibioticresistant infections such as mrsa methicillinresistant staph aureus and influenzaforwardlooking statements this press release contains forwardlooking statements within the meaning of the us federal securities laws forwardlooking statements can be identified by words such as projects may will could would should believes expects anticipates estimates intends plans potential promise or similar references to future periods examples of forwardlooking statements in this press release include without limitation statements regarding dr gilmans opportunity to bring forward contrafects programs and support the companys mission and the companys intention to address lifethreatening conditions using product candidates from its lysin and monoclonal antibody platforms forwardlooking statements are statements that are not historical facts nor assurances of future performance instead they are based on the companys current beliefs expectations and assumptions regarding the future of its business future plans strategies projections anticipated events and trends the economy and other future conditions because forwardlooking statements relate to the future they are subject to inherent risks and uncertainties and actual results may differ materially from those set forth in the forwardlooking statements important factors that could cause actual results to differ include without limitation the company has incurred significant losses since its inception and may never achieve profitability the companys recurring losses from operations could raise substantial doubt regarding its ability to continue as a going concern the company has no product revenues the companys short operating history the companys need for substantial additional funding the company may be required to suspend or discontinue clinical trials due to adverse side effects or other safety risks clinical trials of the companys product candidates are subject to delays which could result in increased costs and jeopardize its ability to obtain regulatory approval and commence product sales as currently contemplated the companys dependence on its license agreements with rockefeller that relate to cf the companys dependence on clinical research organizations the companys lack of experience in bringing a drug to regulatory approval the companys ability to obtain regulatory approval of and commercialize its product candidates the companys ability to attract and retain qualified personnel and changes in management difficulties in managing the companys growth and the important factors described under the caption risk factors in the companys quarterly report on form q filed with the securities and exchange commission the sec on may   and its other filings with the sec any forwardlooking statement made by the company in this press release is based only on information currently available and speaks only as of the date on which it is made except as required by applicable law the company expressly disclaims any obligation to publicly update any forwardlooking statements whether written or oral that may be made from time to time whether as a result of new information future developments or otherwiseread morethe company has filed a registration statement including the preliminary prospectus with the securities and exchange commission the sec for an offering of its common stock and warrants before you invest in that offering you should read the preliminary prospectus in that registration statement for more complete information about the company and the offering you may get these documents for free by visiting edgar on the sec website at wwwsecgov alternatively a copy of the preliminary prospectus may be obtained from the offices of piper jaffray  co attention prospectus department  nicollet mall js minneapolis mn  by telephone   or by email prospectuspjccom you may obtain a copy of the preliminary prospectus at httpswwwsecgovarchivesedgardataindexhtmreblogsharetweetsharerecently viewedyour list is emptywhat to read nextmeg whitmans out will ge chief executive take over ubersiliconbeatthis will be in everyones household by banyan hillsponsoredwind projects in peril as indian states rethink purchasesbloombergamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediamy next car is electrified says shell ceoautoblogengineer finds pattern makes millions in stocksmoney morningsponsoredwhat you need to know on wall street todaybusiness insidertrump names john kelly new chief of staff reince priebus outcnbcthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderzuckerberg wifes ambitious secret finally exposedunewzmesponsorednorth korea nd icbm test puts much of us in range expertsassociated pressall the companies in jeff bezos’s empire in one large chartmarketwatchchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videodiscover it  out of  avg by k customersdiscover cardsponsoredstocks mixed after heavy earnings weekthe real reason overseas manufacturing is coming to americayahoo financedonald trump tweetrages after john mccain kills obamacare skinny repealstan let trump rage mccain you did the right thingjoin the conversation  k